Arixa Pharmaceuticals™ is developing oral antibiotics for resistant Gram-negative infections. The lead program is an oral prodrug of Avibactam®, a broad spectrum beta-lactamase inhibitor recently approved by FDA
Arixa Pharmaceuticals, Inc
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.arixapharma.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
AddressCAPalo AltoUnited States
CA
Palo Alto
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]